Bayer withdraws heart surgery drugBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39395.644826.DB (Published 15 November 2007) Cite this as: BMJ 2007;335:1015
- Annette Tuffs
The German drug company Bayer has suspended worldwide marketing of Trasylol (aprotinin), its antifibrinolytic drug, after the requests of the drug regulating authorities in Germany and Canada and the advice of the Food and Drug Administration in the United States. Infusions of aprotinin have been used to stop excessive bleeding during heart surgery.
A recent Canadian trial known as the BART trial (blood conservation using antifibrinolytics: a randomised trial in high risk cardiac surgery patients), coordinated by the Ottawa Health Research Institute, was stopped because preliminary results showed an increased risk of death from the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial